Clinical Trials — Not Recruiting
Mesothelioma clinical trials listed as “active, not recruiting” are still underway but are no longer enrolling new patients. People already in these studies may still be receiving treatment or follow-up care. Some of these trials have shared early results, while others have no results yet.
Learn About Mesothelioma Clinical Trials in Our Free Guide
What Does “Active, Not Recruiting” Mean?
On ClinicalTrials.gov, the U.S. registry of clinical studies, “active, not recruiting” means a study is ongoing but is not enrolling new participants. People already in the study may still be receiving the treatment being tested or having follow-up exams.
Clinical trials are designed to test new treatments as efficiently as possible. Part of this design means only a certain number of patients can be accepted into each study. A study usually stops enrolling new mesothelioma patients once it reaches this target. In cancer treatment trials, follow-up can continue for years because researchers track how long patients live and whether their cancer grows or returns.
A trial that is not recruiting may not be finished or have results yet. Some trials report results from a planned early analysis while follow-up continues. For instance, the CheckMate 743 clinical trial did this in 2020. It compared the immunotherapy drugs Opdivo® (nivolumab) and Yervoy® (ipilimumab) with standard chemotherapy as a first drug treatment for pleural mesothelioma that cannot be removed with surgery. The trial has since been completed.
In results first reported in 2020 and published in The Lancet in 2021, patients who received Opdivo plus Yervoy had a median overall survival of 18.1 months. Patients who received chemotherapy had a median overall survival of 14.1 months. This means half of the patients in each group lived longer than those times.
Based on these results, the U.S. Food and Drug Administration (FDA) approved Opdivo plus Yervoy in October 2020. The approval covers adults receiving their first drug treatment for pleural mesothelioma that cannot be removed with surgery.
Researchers kept following CheckMate 743 patients after the approval. A 2026 update in the Journal of Clinical Oncology reported 5-year survival rates. The rate was 14% for patients who received Opdivo plus Yervoy and 6% for those who received chemotherapy.
Patients considering a clinical trial can find studies that are still enrolling on our Clinical Trials – Recruiting page.
Ongoing Mesothelioma Clinical Trials Not Recruiting Patients
The studies below are active but are no longer accepting new patients. Some include patients with other types of cancer or focus on topics other than treatment.
Note: The information below is provided by ClinicalTrials.gov. Select a study title to view its full details, including the conditions being studied.
Conditions: Mesothelioma
Last Updated: 11/16/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 11/16/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 11/13/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 11/13/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 11/12/2026
Status: Active, not recruiting
A Beta-only IL-2 ImmunoTherapY Study
Conditions: Mesothelioma
Last Updated: 10/30/2026
Status: Active, not recruiting
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Conditions: Mesothelioma
Last Updated: 10/29/2026
Status: Active, not recruiting
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 10/23/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 10/20/2026
Status: Active, not recruiting
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Conditions: Mesothelioma
Last Updated: 9/30/2026
Status: Active, not recruiting
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
Conditions: Mesothelioma
Last Updated: 9/14/2026
Status: Active, not recruiting
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Conditions: Mesothelioma
Last Updated: 9/11/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 8/25/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 8/11/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 7/31/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 7/27/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 7/22/2026
Status: Active, not recruiting
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Conditions: Mesothelioma
Last Updated: 6/22/2026
Status: Active, not recruiting
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: 6/5/2026
Status: Active, not recruiting
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Conditions: Mesothelioma
Last Updated: 6/1/2026
Status: Active, not recruiting
The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance
Conditions: Mesothelioma
Last Updated: 3/27/2026
Status: Active, not recruiting
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Conditions: Mesothelioma
Last Updated: 3/12/2026
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 12/26/2025
Status: Active, not recruiting
Conditions: Mesothelioma
Last Updated: 11/21/2025
Status: Active, not recruiting
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Conditions: Mesothelioma
Last Updated: 8/27/2025
Status: Active, not recruiting
Sources
Free Mesothelioma Treatment Guide
Dr. Francis Perry Wilson is the Director of the Clinical and Translational Research Accelerator at the Yale University School of Medicine. He specializes in nephrology and clinical research.
Amy Zappone brings nearly two decades of experience in education and research-based communication. At Mesothelioma.com, she translates complex topics into understandable resources that help patients and families make informed decisions.